These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1793062)

  • 1. Development of novel leukotriene--based anti-asthma drugs: MK-886 and MK-571.
    Young RN
    Agents Actions Suppl; 1991; 34():179-87. PubMed ID: 1793062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of the production and action of leukotrienes by MK-571 and MK-886.
    Ford-Hutchinson AW
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():9-16. PubMed ID: 1847788
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist.
    Amirav I; Pawlowski N
    N Engl J Med; 1991 May; 324(18):1288. PubMed ID: 1849613
    [No Abstract]   [Full Text] [Related]  

  • 4. MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human.
    Kips JC; Joos GF; De Lepeleire I; Margolskee DJ; Buntinx A; Pauwels RA; Van der Straeten ME
    Am Rev Respir Dis; 1991 Sep; 144(3 Pt 1):617-21. PubMed ID: 1892302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist.
    Manning PJ; Watson RM; Margolskee DJ; Williams VC; Schwartz JI; O'Byrne PM
    N Engl J Med; 1990 Dec; 323(25):1736-9. PubMed ID: 2174121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiasthmatic effects of a leukotriene biosynthesis inhibitor (MK-0591) in allergic dogs.
    Becker AB; Black C; Lilley MK; Bajwa K; Ford-Hutchinson AW; Simons FE; Tagari P
    J Appl Physiol (1985); 1995 Feb; 78(2):615-22. PubMed ID: 7759431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.
    Prasit P; Belley M; Blouin M; Brideau C; Chan C; Charleson S; Evans JF; Frenette R; Gauthier JY; Guay J
    J Lipid Mediat; 1993; 6(1-3):239-44. PubMed ID: 8357985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects.
    Dahlén B; Margolskee DJ; Zetterström O; Dahlén SE
    Thorax; 1993 Dec; 48(12):1205-10. PubMed ID: 8303624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with MK-571. A potent and specific LTD4 receptor antagonist.
    Margolskee DJ
    Ann N Y Acad Sci; 1991; 629():148-56. PubMed ID: 1659276
    [No Abstract]   [Full Text] [Related]  

  • 10. Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma.
    Rasmussen JB; Eriksson LO; Margolskee DJ; Tagari P; Williams VC; Andersson KE
    J Allergy Clin Immunol; 1992 Aug; 90(2):193-201. PubMed ID: 1323587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma.
    Gaddy JN; Margolskee DJ; Bush RK; Williams VC; Busse WW
    Am Rev Respir Dis; 1992 Aug; 146(2):358-63. PubMed ID: 1489125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cysteinyl leukotriene receptor antagonist MK-571 alters bronchoalveolar lavage fluid proteome in a mouse asthma model.
    Wong WS; Zhu H; Liao W
    Eur J Pharmacol; 2007 Dec; 575(1-3):134-41. PubMed ID: 17689528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukotriene modifiers: novel therapeutic opportunities in asthma.
    Buccellati C; Fumagalli F; Viappiani S; Folco G
    Farmaco; 2002 Mar; 57(3):235-42. PubMed ID: 11989802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571.
    Jones TR; Zamboni R; Belley M; Champion E; Charette L; Ford-Hutchinson AW; Gauthier JY; Leger S; Lord A; Masson P
    Can J Physiol Pharmacol; 1991 Dec; 69(12):1847-54. PubMed ID: 1666333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of LTD(4)in allergic pulmonary inflammation in mice: modulation by cysLT(1)antagonist MK-571.
    Blain JF; Sirois P
    Prostaglandins Leukot Essent Fatty Acids; 2000 Jun; 62(6):361-8. PubMed ID: 10913229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproducibility of leukotriene D4 inhalation challenge in asthmatics. Effect of a novel leukotriene D4/E4-antagonist (SR 2640) on leukotriene D4-induced bronchoconstriction.
    Frølund L; Madsen F; Nielsen J
    Allergy; 1991 Jul; 46(5):355-61. PubMed ID: 1928658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591.
    Tagari P; Becker A; Brideau C; Frenette R; Sadl V; Thomas E; Vickers P; Ford-Hutchinson A
    J Pharmacol Exp Ther; 1993 Apr; 265(1):416-25. PubMed ID: 8386242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Peptidoleukotriene receptor antagonists in asthma therapy].
    Sakakibara H; Hirose K; Okawara S
    Nihon Rinsho; 1996 Nov; 54(11):3049-55. PubMed ID: 8950953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.
    Frenette R; Hutchinson JH; Léger S; Thérien M; Brideau C; Chan CC; Charleson S; Ethier D; Guay J; Jones TR; McAuliffe M; Piechuta H; Riendeau D; Tagari P; Girard Y
    Bioorg Med Chem Lett; 1999 Aug; 9(16):2391-6. PubMed ID: 10476875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model.
    Muz MH; Deveci F; Bulut Y; Ilhan N; Yekeler H; Turgut T
    Exp Mol Med; 2006 Apr; 38(2):109-18. PubMed ID: 16672764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.